TY - JOUR
T1 - Biomimetic proteolipid vesicles for targeting inflamed tissues
AU - Molinaro, Roberto
AU - Corbo, Claudia
AU - Martinez, Jonathan O.
AU - Taraballi, Francesca
AU - Evangelopoulos, Michael
AU - Minardi, Silvia
AU - Yazdi, Iman K.
AU - Zhao, P.
AU - De Rosa, Enrica
AU - Sherman, M. B.
AU - De Vita, Alessandro
AU - Toledano Furman, Naama E.
AU - Wang, X.
AU - Parodi, Alessandro
AU - Tasciotti, Ennio
PY - 2016/5/23
Y1 - 2016/5/23
N2 - A multitude of micro- and nanoparticles have been developed to improve the delivery of systemically administered pharmaceuticals, which are subject to a number of biological barriers that limit their optimal biodistribution. Bioinspired drug-delivery carriers formulated by bottom-up or top-down strategies have emerged as an alternative approach to evade the mononuclear phagocytic system and facilitate transport across the endothelial vessel wall. Here, we describe a method that leverages the advantages of bottom-up and top-down strategies to incorporate proteins derived from the leukocyte plasma membrane into lipid nanoparticles. The resulting proteolipid vesicles—which we refer to as leukosomes—retained the versatility and physicochemical properties typical of liposomal formulations, preferentially targeted inflamed vasculature, enabled the selective and effective delivery of dexamethasone to inflamed tissues, and reduced phlogosis in a localized model of inflammation.
AB - A multitude of micro- and nanoparticles have been developed to improve the delivery of systemically administered pharmaceuticals, which are subject to a number of biological barriers that limit their optimal biodistribution. Bioinspired drug-delivery carriers formulated by bottom-up or top-down strategies have emerged as an alternative approach to evade the mononuclear phagocytic system and facilitate transport across the endothelial vessel wall. Here, we describe a method that leverages the advantages of bottom-up and top-down strategies to incorporate proteins derived from the leukocyte plasma membrane into lipid nanoparticles. The resulting proteolipid vesicles—which we refer to as leukosomes—retained the versatility and physicochemical properties typical of liposomal formulations, preferentially targeted inflamed vasculature, enabled the selective and effective delivery of dexamethasone to inflamed tissues, and reduced phlogosis in a localized model of inflammation.
UR - http://www.scopus.com/inward/record.url?scp=84969883853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969883853&partnerID=8YFLogxK
U2 - 10.1038/nmat4644
DO - 10.1038/nmat4644
M3 - Article
JO - Nature Materials
JF - Nature Materials
SN - 1476-1122
ER -